MedTrace Logo

A Study of MD-120 in Patients With Depression

NCT04345471 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 615

Last updated 2024-02-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to verify the efficacy and evaluate the safety of 8-week once-daily oral administration of MD-120 in Japanese patients with depression.

Conditions

Interventions

DRUG

Desvenlafaxine 100 mg

once daily dosing for 8 weeks

DRUG

Desvenlafaxine 50 mg

once daily dosing for 8 weeks

DRUG

Placebo

once daily dosing for 8 weeks

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Mochida Pharmaceutical Company, Ltd.

    lead INDUSTRY

Principal Investigators

  • Koichi Hayashi · Mochida Pharmaceutical Company, Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-18
Primary Completion
2022-07-21
Completion
2022-09-14

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04345471 on ClinicalTrials.gov